Latest news with #Baxdrostat
Yahoo
14-07-2025
- Business
- Yahoo
AstraZeneca (LSE:AZN) Unveils Promising Phase III Results For Baxdrostat In Hypertension Trial
AstraZeneca recently experienced a weekly price move of 2% amid announcements that could have supported its momentum. The successful Phase III trial results for Baxdrostat, targeting a significant global need for hypertension treatments, likely provided a positive catalyst. Additionally, the European Union's approval of Imfinzi for a new cancer indication may have added further support. These developments occurred against a backdrop of flat overall market performance, with major indexes barely changing as global investors assessed trade policy uncertainties and awaited key financial data releases. We've identified 3 warning signs with AstraZeneca and understanding the impact should be part of your investment process. Find companies with promising cash flow potential yet trading below their fair value. The recent developments for AstraZeneca, particularly the successful Phase III trial results for Baxdrostat and the EU's approval of Imfinzi, could significantly enhance the company's revenue and earnings forecasts. These breakthroughs address substantial medical needs in hypertension and cancer, potentially expanding AstraZeneca's market share and boosting prescription sales. Combined with AstraZeneca's global strategic initiatives, these news items reinforce the company's narrative of growth through innovation and market expansion. Over the past five years, AstraZeneca has achieved a total shareholder return of 25.87%. This long-term performance provides a broader context compared to the recent weekly share price movement of 2%. While AstraZeneca underperformed both the UK market with a return of 5.9% and the UK Pharmaceuticals industry with a negative return of 9.3% over the past year, the strong long-term total returns highlight the company's resilience and potential for enduring growth. As analysts have set a price target of £135.83, approximately 30% above the current share price of £107.28, these recent developments may positively influence future investor sentiment. The new advancements in AstraZeneca's product pipeline and expansion in emerging markets bolster the expectation of future revenue, aligning with analysts' forecasts of significant earnings improvements over the next few years. The current share price discount to the analyst price target could suggest that the market has not yet fully realized the potential upside of these recent achievements. Gain insights into AstraZeneca's future direction by reviewing our growth report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include LSE:AZN. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Time of India
14-07-2025
- Business
- Time of India
AstraZeneca drug lowers high blood pressure in late-stage study
AstraZeneca said on Monday its experimental drug baxdrostat significantly lowered blood pressure in a late-stage trial of patients with treatment-resistant hypertension. The news sent shares of the Anglo-Swedish drugmaker up by almost 2%. The company said it expects peak annual sales for the drug to exceed $5 billion, driven by its use as a standalone therapy and in combination with Farxiga , its blockbuster treatment - one that generates $1 billion or more in annual sales - for type 2 diabetes, heart failure and chronic kidney disease . by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 15 Most Beautiful Female Athletes in the World Click Here Undo Baxdrostat met the main and secondary goals of the study, showing a statistically significant and clinically meaningful reduction in systolic blood pressure at 12 weeks when added to standard treatment at two doses, and compared with placebo, AstraZeneca said. It acquired baxdrostat through its 2023 purchase of CinCor Pharma as part of efforts to expand its pipeline in heart and kidney disease. Live Events The drug targets aldosterone, a hormone that raises blood pressure, offering a new approach distinct from older treatments like ACE inhibitors that do not address hormonal drivers, AstraZeneca says. High blood pressure affects more than 1 billion people worldwide, according to the World Health Organization. AstraZeneca is testing baxdrostat in four indications, including chronic kidney disease and prevention of heart failure, in a clinical programme involving more than 20,000 patients. Shares in London's biggest listed company by market value were up 1.9% at 0834 GMT and among the top gainers on the FTSE 100 index in early trading. Mineralys Therapeutics is developing a similar drug, lorundrostat, and expects to submit data to the U.S. Food and Drug Administration by the end of the year. AstraZeneca said it will present full trial results at a medical conference in August but did not say when it will seek U.S. approval. Its shares are flat this year to date though they have outperformed Europe's benchmark healthcare index by about 5.5%, Barclays analysts said in a note on Monday.
Bloomberg
14-07-2025
- Health
- Bloomberg
Astra Says Potential Blockbuster Reduced High Blood Pressure
AstraZeneca Plc 's experimental hypertension drug Baxdrostat reduced the blood pressure of patients who have an uncontrolled or treatment-resistant form of the condition, boosting the prospects of the medicine becoming a blockbuster. Patients in a late-stage trial received one of two different doses of Baxdrostat or a placebo drug once a day, the drugmaker said Monday. At 12 weeks those on Baxdrostat had a significant and clinically meaningful reduction in systolic blood pressure, which shows how forcefully the heart is pumping blood into arteries.
